Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2010

View Archived Issues

Novel M. tuberculosis methionine aminopeptidase inhibitors identified

Variations in fentanyl sensitivity correlated with OPRM1 gene polymorphisms

Gene recurrence score may be useful for prognosis in node-positive breast cancer

Javelin reports phase III trial data for Ereska

Nymox provides update on pivotal phase III NX-1207 trials for BPH

Phase II study evaluates droxidopa in combination with carbidopa in adult ADHD

StemCells' HuCNS-SC human neural stem cells used in myelination disorder trial

FDA accepts Alexza's AZ-004 NDA for filing

Data Monitoring Committee recommends continuation of phase III StemEx trial

Correlation between higher blood lead levels and adverse mental health outcomes

Oral cladribine reduces rate of multiple sclerosis relapse in phase III trial

LEK Pharmaceuticals describes novel broad spectrum antibacterial agents

Amura Therapeutics discovers novel CAC1 cysteine protease inhibitors

Aegera presents novel IAP inhibitors

Otsuka Pharmaceutical describes novel monoamine reuptake inhibitors

Ligon Discovery and Lycera collaborate to develop drugs for immune disorders

Data Monitoring Committee recommends continuation of phase III ThermoDox trial

QRxPharma initiates second pivotal phase III MoxDuoIR dual-opioid trial

Antisense provides update on ATL-1101

Astellas reports third quarter 2009 results

Lundbeck claims the identification of novel PDE10 inhibitors

FDA grants approval to Daiichi's hypertension treatment Benicar in pediatric patients

Living Cell Technologies receives government grant for Diabecell

3SBio and Ascentage enter into strategic alliance for targeted cancer therapeutics

Shenogen and Chemizon sign agreement for ERalpha receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...